Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Neumic Therapeutics Ltd

University of Otago neuroscience spin-off led by Prof. John Reynolds, with Volpara co-founder Ralph Highnam bringing exit experience.

Dunedin, New Zealand, OceaniaBiotech & life sciences, University therapeutics spin-off (presumed neuroscience)Aotearoa New Zealand
Stage
UndeterminedNo documented AI
Product
R&DNone known
Funding raised
Undisclosedno funding
Founded
20260 years ago
Founders
3John, Ralph…
Global score
3.8Grade DRank 101 of 151

Overview

Young spin-off of the University of Otago led by Prof. John Reynolds, which won the New Zealand final of the Startup World Cup.

Traction

None known

No public evidence of traction found; University of Otago research spin-off at preclinical stage.

Market

Central nervous system therapeutics

Central nervous system therapeutics is a very large but high-failure market where value is created by preclinical proof-of-concept and licensing to pharma. Neumic's indication and pipeline are not public, so the market cannot be assessed precisely. Buyers of such assets are pharma and biotech business development teams. The team combines academic neuroscience with an entrepreneur who exited Volpara.

Addressable market

2025
$123.7B
2030
$160.1B
+5.3% a year

Central nervous system therapeutics: $123.7bn (M2Square, +5.3%/year) to $157bn (IMARC) in 2025; Neumic's indication is not public.

Customers

Pharma and biotech licensees in neuroscience (eventually patients and neurologists).

Who signs the cheque

Pharma business development; investors funding preclinical development.

Geographies

  • New Zealand

Drivers

  • Unmet need in neurological disorders
  • Pharma appetite for in-licensing CNS assets
  • Academic spin-off support

Headwinds

  • Indication and pipeline not public
  • Very long clinical horizon
  • No funding round disclosed

The global CNS therapeutics market is estimated at between $123.7bn (M2Square, +5.3%/year) and $157bn (IMARC) in 2025; Neumic's precise indication is not public.

Scalability 5/10. Potentially global drug once approved, but preclinical stage and indication not public.

Market source: m2squareconsultancy.com

Technology

Category

Therapeutics (preclinical, presumed neuroscience)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

Therapeutics derived from University of Otago research; technical details are not published.

Moat

Unknown: depends on undisclosed IP from Otago research.

Differentiation

Cannot be assessed with available data.

Integration points

  • Preclinical electrophysiology and neural recording tools
  • CRO networks
  • Pharma partnering

Depends on

  • University IP licensing
  • Preclinical funding
  • Regulatory pathway

Use of AI

No use of AI mentioned

Product in detail

not found (therapeutics stemming from University of Otago research; details not published).

Business

Model
Pre-revenue; typical model is licensing or partnering after preclinical/clinical milestones.
Revenue logic
Not applicable yet.
Go-to-market
Academic and investor networks; SWC visibility.

Next milestones

  1. Disclosure of lead indication
  2. Seed round
  3. Preclinical proof-of-concept data

Key risks

  • No public data
  • Long horizon
  • Funding

Opportunities

3 found in the network

Concrete moves for Neumic Therapeutics Ltd inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 1
  • Investors 2

Co-development1

An integration or joint product

High-density neural recording for preclinical readouts

Corticale's SiNAPS probes record brain activity with 1,024 active electrodes. If Neumic's programme involves neural circuit effects, these probes could provide differentiated preclinical electrophysiology data, and Neumic would be a research customer for Corticale.

15%confidence

Evidence from the records

  • “therapeutics stemming from University of Otago research”
  • “SiNAPS probe on a CMOS chip with 1,024 independent active electrodes spaced 30 µm apart.”
If it works
Richer preclinical data for Neumic and a published user lab for Corticale.
First step
Ask Corticale for an academic evaluation programme for its probes.

Investors2

A fund whose thesis fits

Seed round from New Zealand's early-stage investor

Icehouse invests early in Kiwi founders and keeps backing them internationally, from pre-seed to later stages, and backed Neocrete in the network. A University of Otago spin-off with a Volpara co-founder is squarely in its remit.

40%confidence

Evidence from the records

  • “Invest early in Kiwi founders and keep backing them as they scale internationally.”
  • “Co-founder of Volpara Health (AI breast imaging, acquired for ~A$300M).”
If it works
A first institutional seed to fund preclinical work.
First step
Ask Neocrete's CEO for an introduction to the Icehouse partner on its round.

Science-first investor with neurotech in its thesis

Breakout backs founders pairing technology with science, explicitly including neurotech, at Seed and Series A, and led ZymoChem's Series A. Its geography is North America, so this is a medium-fit option once data exist.

15%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Full professor in the Department of Anatomy at the University of Otago, neuroscientist.”
If it works
A US co-investor for a later preclinical round.
First step
Ask ZymoChem's CEO to forward a non-confidential summary to Breakout.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Auckland early-stage VC backing Kiwi founders from pre-seed to growth as they build global companies from New Zealand.

New Zealand university therapeutics spin-off — Kiwi company, a sector gap for Icehouse; stage undetermined.

45%confidence

Evidence from the records

  • “"New Zealand","Oceania"”
  • “University therapeutics spin-off (presumed neuroscience)”
  • “No public evidence of traction found”
Intro path
Founder-to-founder intro via NEOCRETE (network portfolio company of Icehouse Ventures).
First step
Ask Neocrete for an intro; prepare IP and milestone summary.

Sydney early-stage VC backing Australian and New Zealand founders from idea to global scale (Canva, Linktree, ProcurePro).

NZ University of Otago therapeutics spin-off: ANZ origin but preclinical and outside AirTree's visible tech portfolio.

15%confidence

Evidence from the records

  • “University therapeutics spin-off (presumed neuroscience)”
  • “New Zealand”
First step
Low priority; check AirTree interest in biotech first.

Investment analysis

3.8D

Grade D

Rank 101 of 151

Disruption5.0/10
Business model1.0/10
Market7.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early and too opaque; revisit after preclinical data are published.

Disruption

5/10

Therapeutics spin-off in presumed neuroscience: innovation impossible to assess with the available data.

Business model

1/10

No product, no revenue, preclinical stage.

Market

7/10

TAM $123.7bn → base 7; scalability 5/10 (neutral); no international presence: no commercial activity → 7/10.

Risk

9/10

Lower is better

Very high risk: company created in 2026, almost no information, long preclinical pathway.

Strengths

  • Academic and entrepreneurial team (Volpara)
  • National winner

Risks

  • Indication and pipeline not public
  • Very long clinical horizon

Funding

Undisclosed, no funding
  1. antérieur

    research grantsnot specified

    Otago Medical Research Foundation (upstream research, before the spin-off)

  2. 2026-10-28

    prizenot specified

    Winner of the Startup World Cup New Zealand final

Amount used in the study. No funding round; research grants predating incorporation not counted.

Note. no public funding round found

verified, nothing to correct (founding team Reynolds / Highnam / Sweetman confirmed on the website; ultrasound neuromodulation + targeted drug delivery platform; no public funding round).

Team

  • John Reynolds

    Founder & CEO

    Full professor in the Department of Anatomy at the University of Otago, neuroscientist.

  • Ralph Highnam

    Co-founder

    Co-founder of Volpara Health (AI breast imaging, acquired for ~A$300M).

  • Alex Sweetman

    Co-founder & COO

    Operations profile; no detailed public background on the website.

Sources

Regional final
Aotearoa New Zealand
Identification confidence
high
  1. 1otago.ac.nz/news/newsroom/opportunity-to-pitch-work-a-milestone-for-res
  2. 2neumictx.com/team
  3. 3neumictx.com/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet